Real-World Quality-of-Life Outcomes of Axi-Cel Treatment in Lymphoma Subtypes Align With Trial Data

Article

Real-world data associate axicabtagene ciloleucel with temporarily worse quality of life in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma, which improves within 1-year post-infusion.

According to findings presented in a poster presented at the 2022 American Society of Hematology (ASH) Annual Meeting, real-world data from patient-reported outcomes (PROs) suggest that axicabtagene ciloleucel (axi-cel; Yescarta) is associated with temporary worsening of quality of life (QOL) with statistically and clinically significant improvements within 1-year postinfusion in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma.1

To collect QOL and symptomatology data, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30A) was used. Questionnaires were completed at baseline prior to conditioning therapy before axi-cel and at follow-up of 14, 30, 60, 90, 180, and 360 days postinfusion. EORTC data were available for patients at the following times: baseline (n = 53), day 14 (n = 37), day 30 (n = 41), day 60 (n = 39), day 90 (n = 39), day 180 (n = 29), and day 360 (n = 18).

Investigators reported that at 1-year postinfusion with axi-cel global health scores were improved among patients aged 50 to 70 years compared with general population norms. At baseline these scores were matched. Further, physical functioning, role functioning, and social functioning were initially reported below normal for patients with cancer and either returned to or improved from baseline by day 360.1

Of note, emotional functioning was better than the general population at baseline but worsened from day 30 to day 180. Improvements, however, were observed over time, exceeding general population norms by day 360 postinfustion.

In terms of symptomatology, investigators reported that adverse effects including fatigue, insomnia, appetite loss, and constipation improved significantly from baseline to day 360. Improvements were also observed in pain and financial problems; however, at day 180 these effects were worsened.1

“Real-world data suggest that axi-cel is associated with transient worsening of QOL and symptoms at day 14, with significant improvements thereafter in overall QOL and several functional and symptom domains in the year after treatment, said lead study author Heather S. L. Jim, PhD, said in a presentation of the data. “Notably, by 1 year after treatment participants reported overall QOL comparable to the general population.”

“Limited data exist regarding PROs of [chimeric antigen receptor] CAR T-cell therapies with no published longitudinal studies to our knowledge of patients treated as standard of care,” added Jim, who is coleader of the Health Outcomes and Behavior Program at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. “The goal of current study was to report of real-world changes in QOL and symptoms in the first year after treatment with axi-cel.”

“Higher scores on the QOL subscales indicate better QOL and higher scores on the symptom items indicate greater symptomatology,” Lim explained. Clinically meaningful change was defined as a difference of 10 points and scores were compared with normative data from the general population and patients with advanced cancer.2

The analysis included 53 patients with a mean age of 63.23 years (SD, 12.76). Most patients were White (94%) and 20 were women. Eligible patients were English speaking adults who were scheduled to receive axi-cel as standard of care at Moffit Cancer Center for FDA-approved indications. Most patients had diffuse large B cell lymphoma (n = 36), transformed follicular lymphoma (n = 7), or follicular lymphoma (n = 7). Patients had no documented or observable psychiatric or neurological diagnoses that interfere with study participation and were able to provide informed consent.1

“Participants were identified through clinical schedules and tumor boards in consultation with the treating oncologist they were recruited between March 2020 and June 2022,” Lim added.

As a point of comparison with previously published data from the phase 1/2 ZUMA-1 study (NCT02348216), investigators highlighted that 64% of patients would have been eligible for enrollment in the trial.3

Jim concluded by noting that data collected at later timepoints may have been influenced by subsequent treatments or other heath conditions for some patients.

References

  1. Lim HASL, Hoogland AI, Logue JM, et al. Real-world patient-reported outcomes among recipients of axicabtagene ciloleucel for relapsed/refractory large B cell lymphoma. Blood. 2022;140 (suppl 1):5190-5191. doi:10.1182/blood-2022-162337
  2. Quinten C, Coens C, Ghislain I, et al; PROBE; EORTC Clinical Groups. The effects of age on health-related quality of life in cancer populations: a pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer. 2015;51(18):2808-2819. doi:10.1016/j.ejca.2015.08.027
  3. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285-295. doi:10.1016/j.ymthe.2016.10.020
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content